JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.7 0.27

Buy Sell

Overview

Share price change

24h

Current

Min

3.64

Max

3.9

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+258.7% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-32M 222M
Previous open	3.43
Previous close	3.7

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 lut 2026, 23:26 UTC

Major Market Movers

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10 lut 2026, 22:31 UTC

Earnings

Correction to America Movil 4Q Profit Article

10 lut 2026, 22:22 UTC

Earnings

America Movil 4Q Profit Jumps on Lower Financial Costs

10 lut 2026, 23:51 UTC

Market Talk

Earnings

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10 lut 2026, 23:42 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10 lut 2026, 23:40 UTC

Market Talk

Earnings

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10 lut 2026, 23:21 UTC

Market Talk

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10 lut 2026, 23:21 UTC

Market Talk

Global Equities Roundup: Market Talk

10 lut 2026, 22:17 UTC

Market Talk

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10 lut 2026, 22:15 UTC

Earnings

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10 lut 2026, 22:10 UTC

Earnings

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10 lut 2026, 22:10 UTC

Earnings

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10 lut 2026, 22:09 UTC

Earnings

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10 lut 2026, 22:09 UTC

Earnings

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10 lut 2026, 22:01 UTC

Earnings

Intact Financial 4Q EPS C$5.24 >IFC.T

10 lut 2026, 21:54 UTC

Earnings

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10 lut 2026, 21:53 UTC

Earnings

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10 lut 2026, 21:51 UTC

Earnings

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10 lut 2026, 21:51 UTC

Earnings

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 lut 2026, 21:51 UTC

Earnings

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10 lut 2026, 21:51 UTC

Earnings

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10 lut 2026, 21:51 UTC

Earnings

Acquisitions, Mergers, Takeovers

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10 lut 2026, 21:50 UTC

Earnings

Acquisitions, Mergers, Takeovers

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10 lut 2026, 21:50 UTC

Earnings

James Hardie Industries 3Q EPS 12c >JHX

10 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 lut 2026, 21:50 UTC

Earnings

James Hardie Industries 3Q Adj EPS 24c >JHX

10 lut 2026, 21:49 UTC

Earnings

James Hardie Industries 3Q Sales $1.24B >JHX

10 lut 2026, 21:49 UTC

Earnings

Acquisitions, Mergers, Takeovers

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10 lut 2026, 21:48 UTC

Earnings

Acquisitions, Mergers, Takeovers

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10 lut 2026, 21:47 UTC

Earnings

Acquisitions, Mergers, Takeovers

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

258.7% upside

12 Months Forecast

Average 13.2 USD 258.7%

High 25 USD

Low 8 USD

Based on 6 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.